The oral fluoropyrimidines in cancer chemotherapy

Clinical Cancer Research

Volumn 5, Issue 9, 1999, Pages 2289-2296

  Lamont, Elizabeth B ^a   Schilsky, Richard L ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 ETHYNYLURACIL; CAPECITABINE; EMITEFUR; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL DERIVATIVE; TEGAFUR; UFT;

BIOAVAILABILITY; BONE MARROW SUPPRESSION; CANCER; CANCER CHEMOTHERAPY; DRUG ABSORPTION; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG INDICATION; GASTROINTESTINAL DISEASE; HUMAN; NEUROLOGIC DISEASE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SHORT SURVEY;

ADMINISTRATION, ORAL; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; FLUOROURACIL; HUMANS; PRODRUGS; TEGAFUR;

EID: 0032874395     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (75)

1. Heidelberger, C., Chaudhuari, N. K., Danneberg, P., Mooren, D., Griesbach, L., Duschinsky, R., Schnitxer, R. J., Pleven, E., and Scheiner, J. Fluorinated pyrimidines. A new class of tumor inhibitory compounds. Nature (Lond.), 179: 663-666, 1957.
2. nd ed, pp. 149-211. Philadelphia: Lippincott-Raven Publishers, 1996.
3. Fraile, R. J., Baker, L. H., Buroker, T. R., Horwitz, J., and Vaitkevicius, V. K. Pharmacokinetics of 5-fluorouracil administered orally, by rapid intravenous and by slow infusion. Cancer Res., 40: 2223-2228, 1980.
4. Daher, G. C., Harris, B. E., Willard, E. M., and Diasio, R. B. Biochemical basis for circadian-dependent metabolism of fluoropyrimidines. Ann. N. Y. Acad. Sci., 618: 350-361, 1991.
5. McMurrough, J., and McLeod, H. L. Analysis of the dihydropyrimidine dehydrogenase polymorphism in a British population. Br. J. Clin. Pharmacol., 41: 425-427, 1996.
6. Meinsma, R., Fernandez-Salguero, P., Van Kuilenburg, A. B., Van Gennip, A. H., and Gonzalez, F. J. Human polymorphism in drug metabolism: mutation in the dihydropyrimidine dehydrogenase gene results in exon skipping and thymine uracilurea. DNA Cell Biol., 14: 1-6, 1995.
7. Meta-Analysis Group in Cancer. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J. Clin. Oncol., 16: 301-308, 1998.
8. Wolmark, N., Rockette, H., Fisher, B., Wickerham, L., Redmond, C., Fisher, E. R., Jones, J., Mamounas, E. P., Ore, L., Petrelli, N. J., Spurr, C. L., Dimitrov, N., Romond, E. H., Sutherland, C. M., Kardinal, C. G., Defuseco, P. A., and Jochimsen, P. The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: results from National Surgical Adjuvant Breast and Bowel Project Protocol C-03. J. Clin. Oncol., 11: 1879-1887, 1993.
9. International Multicenter Pooled Analysis of Colon Cancer Trials (IMPACT) Investigators. Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. Lancet, 345: 939-944, 1995.
10. Au, J. L., and Sadee, W. The pharmacology of ftorafur (R.S-1-(tetrahydro-2-furanyl)-5-fluorouracil). Recent Res. Cancer Res., 76: 100-114, 1981.
11. Au, J. L., Wu, A. T., Friedman, M. A., and Sadee, W. Pharmacokinetics and metabolism of ftorafur in man. Cancer Treat. Rep., 63: 343-350, 1979.
12. Anttila, M. I., Sotaniemi, E. A., Kairaluoma, M. I., Mokka, R. E., and Sundquist, H. T. Pharmacokinetics of ftorafur after intravenous and oral administration. Cancer Chemother. Pharmacol., 10: 150-153, 1983.
13. Andersen, E., and Pedersen, H. Oral ftorafur versus intravenous 5-fluorouracil. Acta Oncol., 26: 433-436, 1987.
14. Ansfield, F. J., Kallas, G. J., and Singson, J. P. Phase I-II studies of oral tegafur (ftorafur). J. Clin. Oncol., 1: 107-110, 1983.
15. Bjerkeset, T., and Fjosne, H. E. Comparison of oral ftorafur and intravenous 5-fluorouracil in patients with advanced cancer of the stomach, colon, or rectum. Oncology (Basel), 43: 212-215, 1986.
16. Kajanti, M. J., Pyrhonen, S., and Maiche, A. Oral tegafur in the treatment of metastatic breast cancer: Phase II study. Eur. J. Cancer, 29A: 863-866, 1993.
17. Palmeri, S., Gebbia, V., Russo, A., Armata, M. G., Gebbia, N., and Rausa, L. Oral tegafur in the treatment of gastrointestinal tract cancers: a Phase II study. Br. J. Cancer, 61: 475-478, 1990.
18. Bajetta, E., Colleoni, M., Di Bartololmeo, M., Buzzoni, R., Bozzetti, R., Doci, R., Somma, L., Cappuzzo, F., Stampino, C. G., Guenzi, A., Balant, L. P., Zilembo, N., and Di Leo, A. Doxifluridine and leucovorin: an oral treatment combination in advanced colorectal cancer. J. Clin. Oncol., 13: 2613-2619, 1995.
19. Ishitsuka, H., Miwa, M., Ishikawa, T., Ura, M., Sawada, N., Nishida, M., Fukase, Y., Yamamoto, T., More, K., Arasaki, M., Umeda, I., and Shimma, N. Capecitabine: an orally available fluoropyrimidine with tumor selective activity. Proc. Am. Assoc. Cancer Res., 36: 407, 1995.
20. Kono, H., Hara, Y., Sugata, S., Karube, Y., Matsushima, Y., and Ishitsuka, H. Activation of 5′-deoxy-5-fluorouridine by thymidine phosphorylase in human tumors. Chem. Pharm. Bull. (Tokyo), 31: 175-178, 1983.
21. Ishikawa, T., Utoh, M., Sawada, N., Sekiguchi, F., and Ishitsuka, H. Xeloda (capecitabine): an orally available tumor-selective fluoropyrimidine carbamate. Proc. Am. Soc. Clin. Oncol., 16: 208A, 1997.
22. Ishikawa, T., Sawada, N., Sekigichi, F., Fukase, Y., and Ishitsuka, H. Xeloda (capecitabine), a new oral fluoropyrimidine carbamate with an improved efficacy profile over other fluoropyrimidines. Proc. Am. Soc. Clin. Oncol., 16: 796A, 1997.
23. Cao, S., Lu, K., Ishitsuka, H., and Rustum, Y. K. Antitumor efficacy of capecitabine against fluorouracil-sensitive and resistant tumors. Proc. Am. Soc. Clin. Oncol., 16: 795A, 1997.
24. Bajetta, E., Carnaghi, C., Somma, L., and Stampino, C. G. A pilot safety study of capecitabine, a new oral fluoropyrimidine, in patients with advanced neoplastic disease. Tumori, 82: 450-452, 1996.
25. Budman, D. R., Meropol, N. J., Reigner, D., Creaven, P. H., Lichtman, S. M., Berghorn, E., Behr, J., Gordon, R. J., Osterwalder, B., and Griffin, T. Preliminary studies of a novel oral fluoropyrimidine carbamate: capecitabine. J. Clin. Oncol., 16: 1795-1802, 1998.
26. Meropol, N. G., Budman, D. R., Creaven, P. J., Lichtman, S., Berghorn, E., Behr, J., Gordon, R. J., and Osterwalder, B. A Phase I study of continuous twice daily treatment with capecitabine in patients with advanced and/or metastatic solid tumors. Ann. Oncol., 7: 87, 1996.
27. Taguchi, T., Ishitani, K., Saitoh, M., Kurihara, M., Tominaga, T., Fukuyama, Y., Saigenji, K., Toge, T., Takashima, S., Sugimachi, K., and Hara, Y. A Japanese Phase I study of continuous twice-daily treatment with capecitabine in patients with advanced and/or metastatic solid tumours. Ann. Oncol., 7: 87, 1996.
28. Mackean, M., Planting, A., Tweleves, C., Schellens, J., Allman, D., Osterwalder, B., Reigner, B., Griffin, T., Daye, S., and Verweij, J. Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer. J. Clin. Oncol., 16: 2977-2985, 1998.
29. Cassidy, J., Dirix, L., Bissett, D., Reigner, B., Griffin, T., Allman, D., Osterwalder, B., and Van Oosterom, A. T. A Phase I study of capecitabine in combination with oral leucovorin in patients with intractable solid tumors. Clin. Cancer Res., 4: 2755-2761, 1998.
30. O'Shaughnessy, J., Moiseyenko, V., Bell, D., Nabholtz, J. M., Miles, D., Gorbunova, V., Laws, S., Griffin, T., and Osterwalder, B. A randomized Phase II study of Xeloda (capecitabine) versus CMF as first line chemotherapy of breast cancer in women ≥ 55 years. Proc. Am. Soc. Clin. Oncol., 17: 103A, 1998.
31. O'Reilly, S. M., Moiseyenko, V., Talbot, D. C., Gordon, R. J., Griffin, T., and Osterwalder, B. A randomized Phase II study of Xeloda (capecitabine) versus paclitaxel in breast cancer patients failing previous anthracycline therapy. Proc. Am. Soc. Clin. Oncol., 17: 163A, 1998.
32. Findlay, M., Van Cutsem, E., Kocha, W., Allman, D., Laffranchi, B., Griffin, T., Osterwalder, B., Dalley, D., Pazdur, R., and Verweij, J. A randomized Phase II study of Xeloda (capecitabine) in patients with advanced colorectal cancer. Proc. Am. Soc. Clin. Oncol., 16: 227a, 1997.
33. Harper, P., Van Cutsem, E., Thibault, A., Shelygin, Y. A., Twelves, C., Burger, H. U., Allman, D., and Osterwalder, B. A Phase III trial (SO14796) of Xeloda (capecitabine) in previously untreated advanced/ metastatic colorectal cancer. Proc. Am. Soc. Clin. Oncol., 18: 1010, 1999.
34. Cox, J. V., Pazdur, R., Thibault, A., Maroun, J., Weaver, C., Jahn, M. W., Harrison, E., and Griffin, T. A Phase III trial (SO14695) of Xeloda (capecitabine) in previously untreated advanced/metastatic colorectal cancer. Proc. Am. Soc. Clin. Oncol., 18: 1016, 1999.
35. Baccanari, D. P., Davis, S. T., Knick, V. C., and Spector, T. 5-Ethynyluracil: effects on pharmacokinetics and antitumor activity of 5-FU. Proc. Natl. Acad. Sci. USA, 90: 11064-11068, 1993.
36. Baker, S. D., Khor, S. P., Adjei, A. A., Coucette, M., Spector, T., Donehower, R. C., Grochow, L. B., Sartorius, S. E., Noe, D. A., Hohneker, J. A., and Rowinsky, E. K. Pharmacokinetics, oral bioavailability, and safety study of fluorouracil in patients treated with 776C85, an inactivator of dihydropyrimidine dehydrogenase. J. Clin. Oncol., 14: 3085-3096, 1996.
37. Schilsky, R. L., Hohneker, J., Ratain, M. J., Janisch, L., Smetzer, L., Lucas, V. S., Khor, S. P., Diasio, R., Von Hoff, D. D., and Burris, H. A. Phase I clinical and pharmacologic study of eniluracil plus fluorouracil in patients with advanced cancer. J. Clin. Oncol., 16: 1450-1457, 1998.
38. Houyau, P., Gay, C., Chatelut, E., Canal, P., Roche, H., and Milano, G. Severe fluorouracil toxicity in a patient with dihydropyrimidine dehydrogenase deficiency. J. Natl. Cancer Inst., 85: 1602-1603, 1993.
39. Diasio, R. B., Beavers, T. L., and Carpenter, J. T. Familial deficiency of dihydropyrimidine dehydrogenase. J. Clin. Invest., 81: 47-51, 1988.
40. Danenberg, K., Salonga, D., Park, J. M., Leichman, C. G., Leichman, L., Hohnson, M., Diasio, R., and Danenberg, P. Dihydropyrimidine dehydrogenase (DPD) and thymidylate synthase (TS) gene expressions identify a high percentage of colorectal tumors responding to 5-fluorouracil (5-FU). Proc. Am. Soc. Clin. Oncol., 17: 258a, 1998.
41. Etienne, M. C., Cheradame, J. L., Fischel, P., Formento, O., Dassonville, N., Renee, N., Schneider, M., Thyss, A., Demard, F., and Milano, G. Response to fluorouracil therapy in cancer patients: the role of tumoral dihydropyrimidine dehydrogenase activity. J. Clin. Oncol., 13: 1663-1670, 1995.
42. Porter, D. J. T., Chestnut, W. G., Merrill, B. M., and Spector, T. Mechanism-based inactivation of dihydropyrimidine dehydrogenase by 5-ethynyluracil. J. Biol. Chem., 267: 5236-5242, 1992.
43. Spector, T., Harrington, J. A., and Porter, D. J. T. 5-Ethynyluracil (776C85): inactivation of dihydropyrimidine dehydrogenase in vivo. Biochem. Pharmacol., 46: 2243-2248, 1993.
44. Cao, S., Rustum, Y. M., and Spector, T. 5-Ethynyluracil (776C85): modulation of 5-fluorouracil efficacy and therapeutic index in rats bearing advanced colorectal carcinoma. Cancer Res., 54: 1507-1510, 1994.
45. Khor, S. P., Lucas, S., Hsieh, A. Y., Schilsky, R., Burris, H., Von Hoff, D. D., and Spector, T. Effect on renal elimination of 5-fluorouracil (5-FU) and uracil in cancer patients. Proc. Am. Assoc. Cancer Res., 37: 371, 1996.
46. Mani, S., Chevlen, E., Hochster, H., O'Rourke, M., Weaver, C., Bell, W., McGuirt, C., Levin, J., Hohneker, J., and Lokich, J. A Phase II open-label study to evaluate a 28-day regimen of oral 5-fluorouracil (5-FU) plus 776C85 for the treatment of patients with previously untreated metastatic colorectal cancer (CRC). Proc. Am. Soc. Clin. Oncol., 17: 281A, 1998.
47. Shirasaka, T., Nakano, K., Takechi, T., Satake, H., Uchida, J., Fujioka, A., Saito, H., Okabe, H., Oyama, K., Takeda, S., Unemi, N., and Fukushima, M. Antitumor activity of 1 M tegafur, 0.4 M 5-chloro-2,4-dihydroxypyridine and 1 M potassium oxonate (S-1) against human colon carcinoma orthotopically implanted into nude rats. Cancer Res. 56: 2602-2606, 1996.
48. Noorduis, P., Van Groeningen, C. J., Voom, D., Van Kuilenburg, A. B. P., Van Gennip, A. H., Schornagel, J. H., Shirasaka, T., Shimamura, Y., De Vries, M. H., Smid, K., Pinedo, H. M., and Peters, G. J. Pharmacokinetics (PK) of S-1, an oral formulation of ftorafur (FT), oxonic acid (oxo), and 5-chloro-2,4-dihydroxypyridine (CDHP) (molar ratio 1:1:0.4) in patients with solid tumors. Proc. Am. Assoc. Cancer Res., 39: 186, 1998.
49. Taguchi, T., Inuyama, Y., Kanamaru, R., Hasegawa, K., Akazawa, S., Niitani, H., Furue, H., Kurihara, M., Ota, K., Suga, S., Ariyoshi, Y., Takai, S., Shimoyama, T., Toge, T., Takashima, S., Sugimachi, K., Hara, Y., Fujita, H., Kimura, K., Saito, T., Tsukagoshi, S., and Nakao, I. Phase I study of S-1. Gan To Kagaku Ryoho, 24: 2253-2264, 1997.
50. Baba, H., Ohtsu, A., Sakata, Y., Mitachi, Y., Sugimachi, K., and Taguchi, T. Late Phase II study of S-1 in patients with advanced colorectal cancer in Japan. Proc. Am. Soc. Clin. Oncol., 17: 277A, 1998.
51. Ohtsu, A., Sakata, Y., Horikoshi, N., Mitachi, Y., Sugimachi, D., and Taguchi, T. A Phase II study of S-1 in patients with advanced gastric cancer. Proc. Am. Soc. Clin. Oncol., 17: 262A, 1998.
52. Taguchi, T., Horikoshi, N., Kinoshita, H., Toge, T., and Takashima, S. Early Phase II study of S-1 in patients with advanced breast cancer. Proc. Am. Soc. Clin. Oncol., 15: 121, 1996.
53. Inuyama, Y., Kida, A., Tsukuda, M., Kohno, N., and Satake, B. Early Phase II study of S-1 in patients with advanced head and neck cancer. Gan To Kagaku Ryoho, 25: 1151-1158, 1998.
54. Fujii, S., Fukushima, M., Shimamoto, Y., Ohshimo, H., Imaoka, T., and Shirasaka, T. Antitumor activity of BOF-A2, a new 5-fluorouracil derivative. Jpn. J. Cancer Res., 80: 173-181, 1989.
55. Shirasaki, T., Fukushima, M., Shimamoto, Y., Kimura, Y., Ohshimo, H., Imakoka, T., Kimura, A., Utsunomiya, T., and Fujii, S. Metabolic characteristics and antitumor activity of BOF-A2, a new 5-fluorouracil derivative. Jpn. J. Cancer Chemother., 17: 1051-1058, 1990.
56. Shirasaka, T., Fujita, F., Fujita, M., Fukushima, M., Taguchi, T., and Fujii, S. Antitumor activity and metabolism of BOF-A2, a new 5-fluorouracil derivative, with human cancers xenografted into nude mice. Jpn. J. Cancer Chemother., 17: 1871-1876, 1990.
57. Miyauchi, S., Imako, T., Utsunomiya, T., Hayashi, K., Kubo, M., Dawaguchi, T., and Matsui, Y. Oral administration of BOF-A2 to rats with lung transplanted tumors results in increased 5-fluorouracil levels. Jpn. J. Cancer Res., 85: 665-668, 1994.
58. Suzuoki, Y., Saito, T., Taguchi, T., Ohta, K., Furue, H., Niitani, H., Majima, H., Hattori, T., Kumashiro, R., Hasegawa, K., Wakui, A., and Kimura, K. Phase I clinical study of BOF-A2, a new 5-fluorouracil derivative. Proc. Jpn. Cancer Assoc., 49: 374, 1990.
59. Hasegawa, K., Kimura, K., Saito, T., Taguchi, T., Niitani, H., Furue, H., Majima, H., Ohta, K., and Hattori, T. Early Phase II trial of BOF-A2, a new 5-FU derivative. J. Jpn. Soc. Cancer Ther., 25: 2151, 1990.
60. Nakai, Y., Furuse, K., Ohta, M., Yamaguchi, Y., Fuji, M., Asakawa, M., Fukuoka, M., Yoshida, K., and Niitani, H. Efficacy of a new 5-fluorouracil derivative, BOF-A2, in advanced non-small cell lung cancer. Acta Oncol., 33: 523-526, 1994.
61. Fujii, S., Ikenaka, K., Fukushima, M., and Shirasaka, T. Effect of uracil and its derivatives on antitumor activity of 5-fluorouracil and 1-(2-tetrahydrofuryl)-5-fluorouracil. Gann, 69: 763-772, 1978.
62. Fujii, S., Kitano, S., Ikenaka, K., and Shirasaka, T. Effect of coadministration of uracil or cytosine on the antitumor activity of clinical doses of 1-(2-tetrahydrofuryl)-5-fluorouracil and level of 5-fluorouracil in rodents. Gann, 70: 209-214, 1979.
63. Yamamoto, J., Haruno, A., Yoshimura, Y., Unemi, N., Kunimune, Y., Yamashita, K., and Morita, K. Effect of coadministration of uracil on the toxicity of tegafur. J. Pharmacol. Sci., 73: 212-214, 1984.
64. Pazdur, R., Ho, D. H., Lassere, Y., Diaz-Canton, E., Bready, B., and Ho, D. H. Phase I clinical trials of UFT: 5-day and 28-day schedules. Anticancer Drugs, 7: 728-733, 1996.
65. Pazdur, R., Covington, W. P., Brown, N. S., Lassere, Y., Diaz-Canton, E., and Ho, D. H. Comparative steady state pharmacokinetics of oral UFT versus protracted intravenous 5-fluorouracil. Proc. Am. Soc. Clin. Oncol., 15: 474, 1996.
66. Poon, M. A., O'Connell, M. J., Wieand, H. S., Krook, J. E., Gerstner, J. B., Tschetter, L. K., Levitt, R., Kardinal, C. G., and Mailliard, J. A. Biochemical modulation of fluorouracil with leucovorin. Confirmatory evidence of improved therapeutic efficacy in advanced colorectal cancer. J. Clin. Oncol., 9: 1967-1972, 1991.
67. Pazdur, R., Lassere, Y., Diaz-Canton, E., and Ho, D. H. Phase I trial of uracil-tegafur (UFT) plus oral leucovorin: 28-day schedule. Cancer Invest., 16: 145-151, 1998.
68. Pazdur, R. Phase II study of UFT plus leucovorin in colorectal cancer. Oncology (Basel), 54 (Suppl. 1): 19-23, 1997.
69. Carmichael, J., Popiela, T., Radstone, D., Falk, S., Fey, M., Oxa, A., Skovsgaard, T., and Martin, C. Randomized comparative study of Orzel (oral uracil/tegafur (UFT) plus leucovorin (LV) versus parenteral 5-fluorouracil plus leucovorin in patients with metastatic colorectal cancer. Proc. Am. Soc. Clin. Oncol., 18: 1015, 1999.
70. Pazdur, R., Douillard, J-Y., Killings, J. R., Eisenber, P. D., Davidson, N., Harper, P., Vincent, M. D., Lembersky, B. C., and Benner, S. E. Multicenter Phase III study of 5-fluorouracil (5-FU) or UFT in combination with leucovorin (LV) in patients with metastatic colorectal cancer. Proc. Am. Soc. Clin. Oncol., 18: 1009, 1999.
71. Feliu, J., Calvillo, J., Escribano, A., De Castro, J., Espinosa, E., Ordonez, A., Zamora, P., Garcia de Paredes, M. L., De las Heras, B., Jimenez, A., and Gonzalez Baron, M. Neoadjuvant therapy of rectal carcinoma with UFT-folinic acid plus radiotherapy. Proc. Am. Soc. Clin. Oncol., 18: 917, 1999.
72. Lorvidhaya, V., Tonusin, A., Sukthomya, W., Changwiwit, W., and Nimmolrat, A. Induction chemotherapy and irradiation in advanced carcinoma of the cervix. Gan To Kagaku Ryoho, 22 (Suppl. 3): 244-251, 1995.
73. Humerickhouse, R. A., Dolan, M. E., Haraf, D. J., Brockstein, B., Stenson, K., Kies, M., Sulzen, L., Ratain, M. J., and Vokes, E. E. Phase I study of eniluracil, a dihydropyrimidine dehydrogenase inactivator, and oral 5-fluorouracil with radiation therapy in patients with recurrent or advanced head and neck cancer. Clin. Cancer Res., 5: 291-298, 1999.
74. Childs, H., Spencer, S., Raben, D., Tincher, S., Newsome, J., and Robert, F. Phase I study of combined UFT plus leucovorin and radiation therapy for pancreatic cancer. Proc. Am. Soc. Clin. Oncol., 18: 956, 1999.
75. Brito, R., Lassere, Y., Hoff, P., Royce, M., Ravandi, F., Zukowski, T., Janjan, N., Skibber, J., Benner, S., and Pazdur, R. Schedule effect on maximum tolerated dose of Orzel (UFT plus leucovorin). Proc. Am. Soc. Clin. Oncol., 18: 787, 1999.